Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

被引：2
|
作者：
Vogel, Arndt
Kasper, Stefan
Weichert, Wilko
Bitzer, Michael
Block, Andreas
Riess, Hanno
Schulze-Bergkamen, Henning
Moehler, Markus H.
Merx, Kirsten Elisabeth
Endris, Volker
Schnoy, Elisabeth
Siveke, Jens T.
Michl, Patrick
Waldschmidt, Dirk
Kuhlmann, Jan
Geissler, Michael
Kahl, Christoph
Kubicka, Stefan
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Univ Hosp Essen, Dept Med Oncol, West German Canc Ctr, Essen, Germany
[3] Univ Hosp, Inst Pathol, Heidelberg, Germany
[4] Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Med Univ Clin, Tubingen, Germany
[6] Univ Krankenhaus Eppendorf, Hamburg, Germany
[7] Charite, Internist Onkol, D-13353 Berlin, Germany
[8] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany
[9] Johannes Gutenberg Univ Mainz, D-55122 Mainz, Germany
[10] Interdisziplinaren Tumorzentrum Mannheim, Mannheim, Germany
[11] Univ Hosp Regensburg, Dept Internal Med, Regensburg, Germany
[12] Tech Univ Munich, Dept Internal Med 2, D-80290 Munich, Germany
[13] Univ Marburg, Dept Gastroenterol, Marburg, Germany
[14] Univ Cologne, Dept Gastroenterol & Hepatol, D-50931 Cologne, Germany
[15] Univ Hosp Freiburg, Dept Med 2, Freiburg, Germany
[16] Klinikum Esslingen, Dept Gastroenterol & Oncol, Esslingen, Germany
[17] Klinikum Magdeburg, Dept Hematol, Magdeburg, Germany
[18] Canc Ctr Reutlingen, Reutlingen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.4082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4082
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Gefitinib in Combination with Capecitabine as Second-Line Therapy in Patients with Advanced Colorectal Cancer (aCRC): A Phase I/II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Trarbach, Tanja
    Reinacher-Schick, Anke
    Hegewisch-Becker, Susanne
    Vanhoefer, Udo
    Frieling, Thomas
    Lehnert, Lasse
    Schmiegel, Wolff
    Graeven, Ullrich
    [J]. ONKOLOGIE, 2010, 33 (03): : 89 - 93
  • [2] Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine-A Randomized Phase II Trial
    Markussen, Alice
    Jensen, Lars Henrik
    Diness, Laura Vittrup
    Larsen, Finn Ole
    [J]. CANCERS, 2020, 12 (07) : 1 - 10
  • [3] Efficacy of gemcitabine plus erlotinib for rash-positive metastatic pancreatic cancer patients eligible for treatment with FOLFIRINOX - a prospective phase II trial of the "Arbeitsgemeinschaft Internistische Onkologie" - AIO
    Haas, M.
    Boeck, S.
    Siveke, J. T.
    Schenk, M.
    Lerch, M.
    Caca, K.
    Freiberg-Richter, J.
    von Weikersthal, Fischer L.
    Kullmann, F.
    Reinacher-Schick, A.
    Fuchs, M.
    Ettrich, T. J.
    Kanzler, S.
    Kunzmann, V.
    Kruger, S.
    Westphalen, C. B.
    Held, S.
    Heinemann, V.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 207 - +
  • [4] A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer
    Noel, Marcus Smith
    Allen, Jill N.
    Abrams, Thomas Adam
    Yurgelun, Matthew
    Faris, Jason Edward
    Goyal, Lipika
    Clark, Jeffrey W.
    Blaszkowsky, Lawrence Scott
    Murphy, Janet E.
    Zheng, Hui
    Khorana, Alok A.
    Connolly, Gregory Clayton
    Hyrien, Ollivier
    Ng, Kimmie
    Borger, Darrell R.
    Iafrate, Anthony John
    Hezel, Aram F.
    Zhu, Andrew X.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations
    Amin, Nadia Emad Lotfi
    Hansen, Torben Frostrup
    Fernebro, Eva
    Ploen, John
    Eberhard, Jakob
    Lindebjerg, Jan
    Jensen, Lars Henrik
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (01) : 119 - 126
  • [6] A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
    Chen, J. S.
    Hsu, C.
    Chiang, N. J.
    Tsai, C. S.
    Tsou, H. H.
    Huang, S. F.
    Bai, L. Y.
    Chang, I. C.
    Shiah, H. S.
    Ho, C. L.
    Yen, C. J.
    Lee, K. D.
    Chiu, C. F.
    Rau, K. M.
    Yu, M. S.
    Yang, Y.
    Hsieh, R. K.
    Chang, J. Y.
    Shan, Y. S.
    Chao, Y.
    Chen, L. T.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (05) : 943 - 949
  • [7] Phase Ⅰ trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer
    Akinori Watanabe
    Mitsuhiro Kida
    Shiro Miyazawa
    Tomohisa Iwai
    Kosuke Okuwaki
    Toru Kaneko
    Hiroshi Yamauchi
    Miyoko Takezawa
    Hiroshi Imaizumi
    Wasaburo Koizumi
    [J]. World Journal of Gastroenterology, 2015, (19) : 5979 - 5984
  • [8] Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer
    Park, Byung Kyu
    Kim, Yoon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Chung, Jae Bock
    Kim, Kyung Sik
    Choi, Jin-Sub
    Lee, Woo Jung
    Song, Si Young
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 (06) : 999 - 1003
  • [9] A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer
    Kim, ST
    Park, JO
    Lee, J
    Lee, KT
    Lee, JK
    Choi, SH
    Heo, JS
    Park, YS
    Kang, WK
    Park, K
    [J]. CANCER, 2006, 106 (06) : 1339 - 1346
  • [10] Combination Therapy of Gemcitabine and Irinotecan in Advanced Biliary Tract Cancer: Phase II Trial
    Chung, Moon Jae
    Park, Semi
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Song, Si Young
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S761 - S761
12345